Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 52-week, Multicentre Open Label Extension Study of the Safety Tolerability and Efficacy of Donepezil (Aricept) in Parkinson's Disease (PD) Patients With Dementia

NCT01327859 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT01327859
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01327859 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 52-week, Multicentre Open Label Extension Study of the Safety Tolerability and Efficacy of Donepezil (Aricept) in Parkinson's Disease (PD) Patients With Dementia
Lead sponsor
Eisai Inc.
Phase
Phase 3
Overall status
Completed
Start date
March 31, 2003
Completion date
July 31, 2006
Enrollment
357 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

dementia, parkinson's disease